Basiliximab as an Alternative to Antithymocyte Globulin for Early Immunosuppression in Lung Transplantation

Transplantation Proceedings

Volumn 41, Issue 2, 2009, Pages 607-609

  Clinckart, F ^a   Bulpa, P ^a   Jamart, J ^a   Eucher, P ^a   Delaunois, L ^a   Evrard, P ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; CYTOKINE; GLYCOSAMINOGLYCAN POLYSULFATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMPHYSEMA; FEMALE; GRAFT INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; ASPERGILLOSIS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SAFETY; SURVIVAL ANALYSIS; SURVIVORS;

EID: 62849108441     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.12.028     Document Type: Article

References (10)

1. Trulock E., Edwards L., Taylor D., et al., Registry of the International Society for Heart and Lung Transplantation. Twenty-third Official Adult Lung and Heart-Lung Report-2006. J Heart Lung Transplant 25 (2006) 880
2. Valentine V.G., Robbins R.C., Berry G.J., et al. Actuarial survival of heart-lung and bilateral lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 15 (1996) 371
3. Bando K., Paradis I.L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 110 (1995) 4
4. van den Berg J.W., Postma D.S., Koëter G.H., et al. New immunosuppressive drugs and lung transplantation: last or least?. Thorax 54 (1999) 550
5. Boggi U., Vistoli F., Signori S., et al. Efficacy and safety of basiliximab in kidney transplantation. Expert Opin Drug Saf 4 (2005) 473
6. Brennan D., Daller J.A., Lake K.D., et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355 (2006) 1967
7. de la Torre M., Peña E., Calvin M., et al. Basiliximab in lung transplantation: preliminary experience. Transplant Proc 37 (2005) 1534
8. Borro J.M., de la Torre M., Míguelez C., et al. Comparative study of basiliximab treatment in lung transplantation. Transplant Proc 37 (2005) 3996
9. Hachem R., Chakinala M.M., Yusen R.D., et al. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant 24 (2005) 1320
10. Mattei M.F., Redonnet M., Gandjbakhch I., et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26 (2007) 693